Tribendimidine
Treatment for Schistosomiasis
Typical Dosage: 200-400 mg single oral dose
Effectiveness
75%
Safety Score
72%
Clinical Trials
20
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
72
DangerousModerateSafe
Treatment Details
Dosage Range
200-400 mg single oral dose
Time to Effect
Rapid, days to weeks
Treatment Duration
Single dose
Evidence Quality
MODERATENumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
150(Treat 150 patients to see 1 additional serious adverse event)
Confidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$7
Monitoring:$40
Side Effect Mgmt:$15
Total Annual:$62
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$700/QALY
QALYs Gained
0.9
Outcome-Based Costs
Cost per Responder
$72.94
Cost per Remission
$88.57
Comparison vs Praziquantel
Cost Difference
+$7/year
More expensive
QALY Difference
-0.10 QALYs
Worse outcomes
Dominance
No dominance
Prescription Access Economics
Annual Societal Loss per Patient
$189
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$125/year
Time Cost
$40/year
Travel + wait time
Insurance Admin Cost
$20/year
Prior auth, claims
Rx Price
$7/year
Potential OTC Price
$3/year
Estimated if OTC available
Early Treatment Benefit
+0.10 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
MODERATETribendimidine Outcomes
for Schistosomiasis
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+85%
Remission Rate
+70%
Common Side Effects
Abdominal discomfort
+15%
Nausea
+10%
Dizziness
+8%
Headache
+7%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov